Neovacs S.A.
Paris Stock Exchange ALNEV.PA
Neovacs S.A. Price to Sales Ratio (P/S) on January 14, 2025: 0.16
-
Neovacs S.A. 52-week high Price to Sales Ratio (P/S) is 5,094.26 on December 02, 2024, which is 3,126,939.14% above the current Price to Sales Ratio (P/S).
-
Neovacs S.A. 52-week low Price to Sales Ratio (P/S) is 0.16 on January 14, 2025, which is 0.00% below the current Price to Sales Ratio (P/S).
-
Neovacs S.A. average Price to Sales Ratio (P/S) for the last 52 weeks is 663.43.
| Date | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield | Free Cash Flow Yield |
|---|
| CEO | Mr. Hugo Brugiere M.Sc. |
| IPO Date | April 21, 2010 |
| Location | France |
| Headquarters | 3-5, Impasse Reille |
| Employees | 22 |
| Sector | Health Care |
| Industries | |
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Past 5 years
USD 1.74
USD 1.88
StockViz Staff
January 15, 2025
Any question? Send us an email